(VIANEWS) – The Market ended the session with NYKODE THERAPEUTIC (NYKD.OL) rising 21.63% to kr29.02 on Wednesday while Oslo Børs Benchmark Index_GI fell 0.6% to kr1,220.72.
NYKODE THERAPEUTIC’s last close was kr23.86, 42.73% under its 52-week high of kr41.66.
About NYKODE THERAPEUTIC
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of melanoma, lung, head and neck, renal, and bladder cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2007 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, NYKODE THERAPEUTIC has a trailing twelve months EPS of kr-0.75.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.35%.
Yearly Top and Bottom Value
NYKODE THERAPEUTIC’s stock is valued at kr29.02 at 22:32 EST, way under its 52-week high of kr41.66 and way higher than its 52-week low of kr20.18.
Volume
Today’s last reported volume for NYKODE THERAPEUTIC is 3180700 which is 492.64% above its average volume of 536697.
Moving Average
NYKODE THERAPEUTIC’s worth is way above its 50-day moving average of kr26.10 and above its 200-day moving average of kr28.75.
More news about NYKODE THERAPEUTIC (NYKD.OL).
